|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hendon SE and DiPalma JA: U.S. practices
for colon cancer screening. Keio J Med. 54:179–183. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Miura N, Wanaka A, Tohyama M and Tanaka K:
MFH-1, a new member of the fork head domain family, is expressed in
developing mesenchyme. FEBS Lett. 326:171–176. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nishida N, Mimori K, Yokobori T, Sudo T,
Tanaka F, Shibata K, Ishii H, Doki Y and Mori M: FOXC2 is a novel
prognostic factor in human esophageal squamous cell carcinoma. Ann
Surg Oncol. 18:535–542. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hollier BG, Tinnirello AA, Werden SJ,
Evans KW, Taube JH, Sarkar TR, Sphyris N, Shariati M, Kumar SV,
Battula VL, et al: FOXC2 expression links epithelial-mesenchymal
transition and stem cell properties in breast cancer. Cancer Res.
73:1981–1992. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
van der Heul-Nieuwenhuijsen L, Dits NF and
Jenster G: Gene expression of forkhead transcription factors in the
normal and diseased human prostate. BJU Int. 103:1574–1580. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Papanicolaou KN, Izumiya Y and Walsh K:
Forkhead transcription factors and cardiovascular biology. Circ
Res. 102:16–31. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sano H, Leboeuf JP, Novitskiy SV, Seo S,
Zaja-Milatovic S, Dikov MM and Kume T: The Foxc2 transcription
factor regulates tumor angiogenesis. Biochem Biophys Res Commun.
392:201–206. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kume T: Foxc2 transcription factor: A
newly described regulator of angiogenesis. Trends Cardiovasc Med.
18:224–228. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Watanabe T, Kobunai T, Yamamoto Y, Matsuda
K, Ishihara S, Nozawa K, Iinuma H, Kanazawa T, Tanaka T, Konishi T,
et al: Gene expression of mesenchyme forkhead 1 (FOXC2)
significantly correlates with the degree of lymph node metastasis
in colorectal cancer. Int Surg. 96:207–216. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Subramanya RD, Coda AB and Sinha AA:
Transcriptional profiling in alopecia areata defines immune and
cell cycle control related genes within disease-specific
signatures. Genomics. 96:146–153. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Petrova TV, Karpanen T, Norrmén C, Mellor
R, Tamakoshi T, Finegold D, Ferrell R, Kerjaschki D, Mortimer P,
Ylä-Herttuala S, et al: Defective valves and abnormal mural cell
recruitment underlie lymphatic vascular failure in lymphedema
distichiasis. Nat Med. 10:974–981. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cui YM, Jiang D, Zhang SH, Wu P, Ye YP,
Chen CM, Tang N, Liang L, Li TT, Qi L, et al: FOXC2 promotes
colorectal cancer proliferation through inhibition of FOXO3a and
activation of MAPK and AKT signaling pathways. Cancer Lett.
353:87–94. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Likhite N and Warawdekar UM: A unique
method for isolation and solubilization of proteins after
extraction of RNA from tumor tissue using trizol. J Biomol Tech.
22:37–44. 2011.PubMed/NCBI
|
|
15
|
Mani SA, Yang J, Brooks M, Schwaninger G,
Zhou A, Miura N, Kutok JL, Hartwell K, Richardson AL and Weinberg
RA: Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis
and is associated with aggressive basal-like breast cancers. Proc
Natl Acad Sci USA. 104:10069–10074. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hahn WC, Dessain SK, Brooks MW, King JE,
Elenbaas B, Sabatini DM, DeCaprio JA and Weinberg RA: Enumeration
of the simian virus 40 early region elements necessary for human
cell transformation. Mol Cell Biol. 22:2111–2123. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liao WT, Wang X, Xu LH, Kong QL, Yu CP, Li
MZ, Shi L, Zeng MS and Song LB: Centromere protein H is a novel
prognostic marker for human nonsmall cell lung cancer progression
and overall patient survival. Cancer. 115:1507–1517. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vara Fresno JA, Casado E, de Castro J,
Cejas P, Belda-Iniesta C and González-Barón P: PI3K/Akt signalling
pathway and cancer. Cancer Treat Rev. 30:193–204. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Massagué J: G1 cell-cycle control and
cancer. Nature. 432:298–306. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Watanabe A, Suzuki H, Yokobori T, Altan B,
Kubo N, Araki K, Wada S, Mochida Y, Sasaki S, Kashiwabara K, et al:
Forkhead box protein C2 contributes to invasion and metastasis of
extrahepatic cholangiocarcinoma, resulting in a poor prognosis.
Cancer Sci. 104:1427–1432. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu JJ, Lin M, Yu JY, Liu B and Bao JK:
Targeting apoptotic and autophagic pathways for cancer
therapeutics. Cancer Lett. 300:105–114. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Denicourt C and Dowdy SF: Medicine.
Targeting apoptotic pathways in cancer cells. Science.
305:1411–1413. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hougardy BM, Maduro JH, van der Zee AG,
Willemse PH, de Jong S and de Vries EG: Clinical potential of
inhibitors of survival pathways and activators of apoptotic
pathways in treatment of cervical cancer: Changing the apoptotic
balance. Lancet Oncol. 6:589–598. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kang MH and Reynolds CP: Bcl-2 inhibitors:
Targeting mitochondrial apoptotic pathways in cancer therapy. Clin
Cancer Res. 15:1126–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rinn JL, Wang JK, Allen N, Brugmann SA,
Mikels AJ, Liu H, Ridky TW, Stadler HS, Nusse R, Helms JA and Chang
HY: A dermal HOX transcriptional program regulates site-specific
epidermal fate. Genes Dev. 22:303–307. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Leonis MA, Thobe MN and Waltz SE:
Ron-receptor tyrosine kinase in tumorigenesis and metastasis.
Future Oncol. 3:441–448. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tsuchiya T, Tsuno NH, Asakage M, Yamada J,
Yoneyama S, Okaji Y, Sasaki S, Kitayama J, Osada T, Takahashi K and
Nagawa H: Apoptosis induction by p38 MAPK inhibitor in human colon
cancer cells. Hepatogastroenterology. 55:930–935. 2008.PubMed/NCBI
|
|
30
|
Mao JD, Wu P, Huang JX, Wu J and Yang G:
Role of ERK-MAPK signaling pathway in pentagastrin-regulated growth
of large intestinal carcinoma. World J Gastroenterol.
20:12542–12550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Esmaeili MA, Farimani MM and Kiaei M:
Anticancer effect of calycopterin via PI3K/Akt and MAPK signaling
pathways, ROS-mediated pathway and mitochondrial dysfunction in
hepatoblastoma cancer (HepG2) cells. Mol Cell Biochem. 397:17–31.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen JY, Zhang L, Zhang H, Su L and Qin
LP: Triggering of p38 MAPK and JNK signaling is important for
oleanolic acid-induced apoptosis via the mitochondrial death
pathway in hypertrophic scar fibroblasts. Phytother Res.
28:1468–1478. 2014. View
Article : Google Scholar : PubMed/NCBI
|
